Pharmacokinetics of Pimozide in Adults and Children with Tourette's Syndrome

Pimozide is a neuroleptic drug with dopamine receptor and calcium channel blocking activity that is used in the treatment of Tourette's syndrome. A comparison of the pharmacokinetics of pimozide was made in children and adults with Tourette's syndrome. Seven adults (ages 23–39) and four children (ages 6–13) received a single 2‐mg oral dose of pimozide and a minimum of nine blood samples were collected over a four‐day period. Mean elimination half‐life of pimozide in children was 66 hours compared with 111 hours in adults with Tourette's syndrome. Significant interindividual variability of pimozide pharmacokinetics was found in both adults and children with Tourette's syndrome. The pharmacokinetics of pimozide in patients with Tourette's syndrome differs from that reported in adult populations with chronic schizophrenia.

[1]  B. Pakkenberg,et al.  Clinical features and long-term treatment with pimozide in 65 patients with Gilles de la Tourette's syndrome. , 1986, Journal of neurology, neurosurgery, and psychiatry.

[2]  S. Rasmussen,et al.  Clonidine in the treatment of Tourette's syndrome exacerbation due to haloperidol withdrawal. , 1986, The Journal of nervous and mental disease.

[3]  A. Shapiro,et al.  Treatment of Gilles de la Tourette syndrome with pimozide. , 1983, The American journal of psychiatry.

[4]  S. Snyder,et al.  Antischizophrenic drugs of the diphenylbutylpiperidine type act as calcium channel antagonists. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[5]  Borison Rl,et al.  Site-specific blockade of dopamine receptors by neuroleptic agents in human brain. , 1981 .

[6]  J. Heykants,et al.  Plasma pimozide profiles in chronic schizophrenics. , 1979, British journal of clinical pharmacology.

[7]  J. Kebabian,et al.  Multiple receptors for dopamine , 1979, Nature.

[8]  J. Wagner,et al.  CSTRIP, a fortran IV computer program for obtaining initial polyexponential parameter estimates. , 1976, Journal of pharmaceutical sciences.

[9]  P. Janssen,et al.  Radioimmunoassay of the neuroleptic drug pimozide. , 1975, Life sciences.

[10]  J. P. Costiloe,et al.  Pimozide in chronic schizophrenic outpatients. , 1975, Diseases of the nervous system.

[11]  J. Heykants,et al.  [Absorption, metabolism and excretion of pimozide in man]. , 1972, La Clinica terapeutica.

[12]  U. Ungerstedt,et al.  Receptor activity and turnover of dopamine and noradrenaline after neuroleptics. , 1970, European journal of pharmacology.

[13]  W. Soudijn,et al.  The metabolism and excretion of the neuroleptic drug pimozide (R 6238) by the wistar rat. , 1969, Life sciences.

[14]  P. Janssen,et al.  Pimozide, a chemically novel, highly potent and orally long-acting neuroleptic drug. 3. Regional distribution of pimozide and of haloperidol in the dog brain. , 1968, Arzneimittel-Forschung.

[15]  Janssen Pa,et al.  Pimozide, a chemically novel, highly potent and orally long-acting neuroleptic drug. II. Kinetic study of the distribution of pimozide and metabolites in brain, liver, and blood of the Wistar rat. , 1968 .

[16]  Pimozide for Tourette's disorder. , 1985, The Medical letter on drugs and therapeutics.

[17]  J. Fields,et al.  Site-specific blockade of dopamine receptors by neuroleptic agents in human brain. , 1981, Neuropharmacology.

[18]  T Nakagawa,et al.  A pharmacokinetic analysis program (multi) for microcomputer. , 1981, Journal of pharmacobio-dynamics.